<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03241927</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 16-2526</org_study_id>
    <nct_id>NCT03241927</nct_id>
  </id_info>
  <brief_title>Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)</brief_title>
  <official_title>A Phase II Study Assessing the Effect of Pembrolizumab Induced Changes to the NK Cell Exhaustion Phenotype on the Efficacy of PD-1 Targeted Treatment in Patients With Unresectable Stage III or Stage IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nina Bhardwaj</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Melanoma is an immune-modulated malignancy and immune checkpoint modulators which inhibit&#xD;
      PD-1 function (pembrolizumab, nivolumab) have demonstrated clinical efficacy as treatment for&#xD;
      patients with stage IV melanoma. Pembrolizumab across a range of doses in phase I&#xD;
      investigation has demonstrated clinical efficacy with RR approximately 27%. By better&#xD;
      understanding how NK cell function and exhaustion interplays with PD1 function and activity,&#xD;
      potentially more efficacious combination therapies can be developed. The pharmacodynamic&#xD;
      studies to be performed as part of this trial will provide such information.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficult enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Actual">June 6, 2018</completion_date>
  <primary_completion_date type="Actual">June 6, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of LAMP-1 Positive Cells</measure>
    <time_frame>up to 3 years</time_frame>
    <description>NK cell exhaustion will be assess by flow cytometry and expressed as % of LAMP-1 positive cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Positive Cell for IFN Gamma</measure>
    <time_frame>up to 3 years</time_frame>
    <description>IFN gamma will be assess by flow cytometry and then expressed as % of positive cell for IFN gamma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Proliferating Cells</measure>
    <time_frame>up to 3 years</time_frame>
    <description>NK proliferation will be assess by flow cytometry and then expressed as percentage of proliferating cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MICA Plasma Level</measure>
    <time_frame>up to 104 levels</time_frame>
    <description>MICA plasma biomarker level associated with reversal of NK cell exhaustion will be assessed by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HMGB-1 Plasma Level</measure>
    <time_frame>up to 104 weeks</time_frame>
    <description>HMGB-1 plasma biomarker level associated with reversal of NK cell exhaustion will be assessed by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Positive NK Cells for CEACAM-1</measure>
    <time_frame>up to 104 weeks</time_frame>
    <description>CEACAM-1 expression will be assessed by flow cytometry and express as % of positive NK cells for CEACAM-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <description>One year survival following pembrolizumab treatment in patients with Unresectable stage III or IV melanoma using Immune-Related Response Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Progression free survival in pembrolizumab treated patients with unresectable stage III or IV melanoma using Immune-Related Response Criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg IV infusion every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Donors</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Day 1 of each 3 week cycle</description>
    <arm_group_label>Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be willing and able to provide written informed consent/assent for the trial.&#xD;
&#xD;
          -  Have Unresectable stage III or stage IV melanoma&#xD;
&#xD;
          -  Be ≥ 18 years of age on day of signing informed consent.&#xD;
&#xD;
          -  Have measurable disease based on RECIST 1.1 and be able to be followed over time by&#xD;
             Immune related response criteria (irRC) for treatment decisions.&#xD;
&#xD;
          -  Have a performance status of 0, 1, or 2 on the ECOG Performance Scale.&#xD;
&#xD;
          -  Demonstrate adequate organ function as defined in Table 1, all screening labs should&#xD;
             be performed within 10 days of treatment initiation.&#xD;
&#xD;
          -  Female subjects of childbearing potential should have a negative urine or serum&#xD;
             pregnancy within 72 hours prior to receiving the first dose of study medication. If&#xD;
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test&#xD;
             will be required.&#xD;
&#xD;
          -  Female subjects of childbearing potential should be willing to use 2 methods of birth&#xD;
             control or be surgically sterile, or abstain from heterosexual activity for the course&#xD;
             of the study through 120 days after the last dose of study medication (Reference&#xD;
             Section 5.6.2). Subjects of childbearing potential are those who have not been&#xD;
             surgically sterilized or have not been free from menses for &gt; 1 year.&#xD;
&#xD;
          -  Male subjects should agree to use an adequate method of contraception starting with&#xD;
             the first dose of study therapy through 120 days after the last dose of study therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is currently participating and receiving study therapy or has participated in a study&#xD;
             of an investigational agent and received study therapy or used an investigational&#xD;
             device within 4 weeks prior to the first dose of treatment.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of systemic immunosuppressive therapy within 7 days prior to the first dose&#xD;
             of trial treatment. Topical, inhaled, ocular, and intra-articular steroids are not&#xD;
             exclusionary.&#xD;
&#xD;
          -  Has a known history of active TB (Bacillus Tuberculosis).&#xD;
&#xD;
          -  Hypersensitivity to pembrolizumab or any of its excipients.&#xD;
&#xD;
          -  Has had a prior anti-cancer monoclonal antibody (mAb) treatment within 4 weeks prior&#xD;
             to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse&#xD;
             events due to agents administered more than 4 weeks earlier.&#xD;
&#xD;
          -  Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy&#xD;
             within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at&#xD;
             baseline) from adverse events due to a previously administered agent. - Note: Subjects&#xD;
             with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the&#xD;
             study.&#xD;
&#xD;
          -  Note: If subject received major surgery, the subject must have recovered adequately&#xD;
             from the toxicity and/or complications from the intervention prior to starting&#xD;
             therapy.&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the&#xD;
             skin that has undergone potentially curative therapy or in situ cervical cancer&#xD;
&#xD;
          -  Has known active central nervous system (CNS) metastases and/or carcinomatous&#xD;
             meningitis. Subjects with previously treated brain metastases may participate provided&#xD;
             the subjects are stable (without evidence of progression by imaging for at least four&#xD;
             weeks prior to the first dose of trial treatment and any neurologic symptoms have&#xD;
             returned to baseline), have no evidence of new or enlarging brain metastases, and are&#xD;
             not using steroids for at least 7 days prior to trial treatment. This exception does&#xD;
             not include carcinomatous meningitis, which is excluded regardless of clinical&#xD;
             stability.&#xD;
&#xD;
          -  Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (eg. thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
          -  Has a history of (non-infectious) pneumonitis that required steroids or current&#xD;
             pneumonitis.&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy.&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
          -  Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
          -  If pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment.&#xD;
&#xD;
          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.&#xD;
&#xD;
          -  Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
          -  Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected).&#xD;
&#xD;
          -  Has received a live vaccine within 30 days of planned start of study therapy.&#xD;
&#xD;
          -  Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines&#xD;
             and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live&#xD;
             attenuated vaccines and are not allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Bhardwaj, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 2, 2017</study_first_submitted>
  <study_first_submitted_qc>August 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2017</study_first_posted>
  <results_first_submitted>October 29, 2020</results_first_submitted>
  <results_first_submitted_qc>October 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 23, 2020</results_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Nina Bhardwaj</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pembrolizumab</keyword>
  <keyword>NK Cell Exhaustion</keyword>
  <keyword>PD-1</keyword>
  <keyword>Unresectable</keyword>
  <keyword>Stage III</keyword>
  <keyword>Stage IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT03241927/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>4 Participants consented, 1 with unstable CNS and not eligible, 2 withdrew consent. and 1 enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pembrolizumab</title>
          <description>200 mg IV infusion every 3 weeks&#xD;
Pembrolizumab: Day 1 of each 3 week cycle</description>
        </group>
        <group group_id="P2">
          <title>Healthy Donors</title>
          <description>Healthy participants</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>study terminated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pembrolizumab</title>
          <description>200 mg IV infusion every 3 weeks&#xD;
Pembrolizumab: Day 1 of each 3 week cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of LAMP-1 Positive Cells</title>
        <description>NK cell exhaustion will be assess by flow cytometry and expressed as % of LAMP-1 positive cells.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>200 mg IV infusion every 3 weeks&#xD;
Pembrolizumab: Day 1 of each 3 week cycle</description>
          </group>
          <group group_id="O2">
            <title>Healthy Donors</title>
            <description>Healthy participants</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of LAMP-1 Positive Cells</title>
          <description>NK cell exhaustion will be assess by flow cytometry and expressed as % of LAMP-1 positive cells.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Positive Cell for IFN Gamma</title>
        <description>IFN gamma will be assess by flow cytometry and then expressed as % of positive cell for IFN gamma.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>200 mg IV infusion every 3 weeks&#xD;
Pembrolizumab: Day 1 of each 3 week cycle</description>
          </group>
          <group group_id="O2">
            <title>Healthy Donors</title>
            <description>Healthy participants</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Positive Cell for IFN Gamma</title>
          <description>IFN gamma will be assess by flow cytometry and then expressed as % of positive cell for IFN gamma.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Proliferating Cells</title>
        <description>NK proliferation will be assess by flow cytometry and then expressed as percentage of proliferating cells.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>200 mg IV infusion every 3 weeks&#xD;
Pembrolizumab: Day 1 of each 3 week cycle</description>
          </group>
          <group group_id="O2">
            <title>Healthy Donors</title>
            <description>Healthy participants</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Proliferating Cells</title>
          <description>NK proliferation will be assess by flow cytometry and then expressed as percentage of proliferating cells.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MICA Plasma Level</title>
        <description>MICA plasma biomarker level associated with reversal of NK cell exhaustion will be assessed by ELISA.</description>
        <time_frame>up to 104 levels</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>200 mg IV infusion every 3 weeks&#xD;
Pembrolizumab: Day 1 of each 3 week cycle</description>
          </group>
          <group group_id="O2">
            <title>Healthy Donors</title>
            <description>Healthy participants</description>
          </group>
        </group_list>
        <measure>
          <title>MICA Plasma Level</title>
          <description>MICA plasma biomarker level associated with reversal of NK cell exhaustion will be assessed by ELISA.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HMGB-1 Plasma Level</title>
        <description>HMGB-1 plasma biomarker level associated with reversal of NK cell exhaustion will be assessed by ELISA.</description>
        <time_frame>up to 104 weeks</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>200 mg IV infusion every 3 weeks&#xD;
Pembrolizumab: Day 1 of each 3 week cycle</description>
          </group>
          <group group_id="O2">
            <title>Healthy Donors</title>
            <description>Healthy participants</description>
          </group>
        </group_list>
        <measure>
          <title>HMGB-1 Plasma Level</title>
          <description>HMGB-1 plasma biomarker level associated with reversal of NK cell exhaustion will be assessed by ELISA.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Positive NK Cells for CEACAM-1</title>
        <description>CEACAM-1 expression will be assessed by flow cytometry and express as % of positive NK cells for CEACAM-1</description>
        <time_frame>up to 104 weeks</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>200 mg IV infusion every 3 weeks&#xD;
Pembrolizumab: Day 1 of each 3 week cycle</description>
          </group>
          <group group_id="O2">
            <title>Healthy Donors</title>
            <description>Healthy participants</description>
          </group>
        </group_list>
        <measure>
          <title>% of Positive NK Cells for CEACAM-1</title>
          <description>CEACAM-1 expression will be assessed by flow cytometry and express as % of positive NK cells for CEACAM-1</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Overall Survival</title>
        <description>One year survival following pembrolizumab treatment in patients with Unresectable stage III or IV melanoma using Immune-Related Response Criteria.</description>
        <time_frame>1 year</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>200 mg IV infusion every 3 weeks&#xD;
Pembrolizumab: Day 1 of each 3 week cycle</description>
          </group>
          <group group_id="O2">
            <title>Healthy Donors</title>
            <description>Healthy participants</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Overall Survival</title>
          <description>One year survival following pembrolizumab treatment in patients with Unresectable stage III or IV melanoma using Immune-Related Response Criteria.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) Rate</title>
        <description>Progression free survival in pembrolizumab treated patients with unresectable stage III or IV melanoma using Immune-Related Response Criteria.</description>
        <time_frame>6 months</time_frame>
        <population>only one subject in study</population>
        <group_list>
          <group group_id="O1">
            <title>Pembrolizumab</title>
            <description>200 mg IV infusion every 3 weeks&#xD;
Pembrolizumab: Day 1 of each 3 week cycle</description>
          </group>
          <group group_id="O2">
            <title>Healthy Donors</title>
            <description>Healthy participants</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) Rate</title>
          <description>Progression free survival in pembrolizumab treated patients with unresectable stage III or IV melanoma using Immune-Related Response Criteria.</description>
          <population>only one subject in study</population>
          <units>weeks</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 weeks</time_frame>
      <desc>there was only one person in this study. No participants in Healthy Control arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pembrolizumab</title>
          <description>200 mg IV infusion every 3 weeks&#xD;
Pembrolizumab: Day 1 of each 3 week cycle</description>
        </group>
        <group group_id="E2">
          <title>Healthy Control</title>
          <description>Healthy Participants</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral Leg Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair thinning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nina Bhardwaj</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-824-8427</phone>
      <email>nina.bhardwaj@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

